News

Avammune Therapeutics raises $12 million to advance cancer therapies

Publications

AVA-NP-695 Selectively Inhibits ENPP1 to Activate STING Pathway and Abrogate Tumor Metastasis in 4T1 Breast Cancer Syngeneic Mouse Model.
Avijit Goswami, Barnali Deb, Sandeep Goyal, Abhishek Gosavi, Mukund Mali, Ashwita M. Martis, Princy Khurana, Mukesh Gangar, Digambar Raykar, Ankita Mohanty and Aditya Kulkarni

Molecules. October 2022, 27, 6721

Design, synthesis and biological evaluation studies of novel small molecule ENPP1 inhibitors for cancer immunotherapy.
Mukesh Gangar, Sandeep Goyal, Digambar Raykar, Princy Khurana, Ashwita M. Martis, Avijit Goswami, Ishani Ghoshal, Ketul V. Patel, Yadav Nagare, Santosh Raikar, Apurba Mukherjee, Rajath Cyriac, Jean-François Paquin, Aditya Kulkarni

Bioorganic Chemistry. December 2021, 0045-2068/© 2021 Elsevier Inc.

Conference Abstracts

1179 Discovery of a first-in-class ADAR1 p150 inhibitor targeting the Zα-domain with potent anti-tumor efficacy in syngeneic mouse models
Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2025, 13 (Suppl 2) A1344; DOI:10.1136/jitc-2025-SITC2025.1179

624 AVA-NP-695 demonstrates strong anti-cancer activity in ICB-refractory & rare cancers
Borja Ruiz Fernandez de Cordoba, Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Alejandro Sweet-cordero, Aditya Kulkarni

Journal for ImmunoTherapy of Cancer Nov 2025, 13 (Suppl 2) A710; DOI:10.1136/jitc-2025-SITC2025.0624

Reach out to us

→

USA

Avammune Therapeutics, Inc. Pennsylvania

India

Avammune Lifesciences Private Limited #545/6, 1st Floor, Devarachikkanahalli Main Road, Bommanahalli, Bangalore 560068
080-41268499
© 2026 Avammune Therapeutics